| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Piperidones | 16 | 2019 | 32 | 6.040 |
Why?
|
| Benzylidene Compounds | 14 | 2019 | 29 | 5.600 |
Why?
|
| Shock, Hemorrhagic | 10 | 2018 | 47 | 4.600 |
Why?
|
| Hemoglobins | 12 | 2016 | 116 | 3.890 |
Why?
|
| Liposomes | 18 | 2016 | 142 | 3.630 |
Why?
|
| Positron-Emission Tomography | 12 | 2022 | 98 | 2.990 |
Why?
|
| Radiopharmaceuticals | 10 | 2019 | 68 | 2.610 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 657 | 1.950 |
Why?
|
| Animals | 63 | 2024 | 9963 | 1.910 |
Why?
|
| Technetium | 12 | 2021 | 43 | 1.800 |
Why?
|
| Fluorine Radioisotopes | 7 | 2017 | 26 | 1.740 |
Why?
|
| Blood Substitutes | 5 | 2015 | 9 | 1.700 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 342 | 1.640 |
Why?
|
| Rats | 25 | 2018 | 1546 | 1.610 |
Why?
|
| Rats, Sprague-Dawley | 21 | 2016 | 545 | 1.550 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2022 | 110 | 1.540 |
Why?
|
| Glucaric Acid | 3 | 2022 | 10 | 1.510 |
Why?
|
| Lung Neoplasms | 5 | 2014 | 338 | 1.500 |
Why?
|
| Brain | 5 | 2020 | 699 | 1.500 |
Why?
|
| Disease Models, Animal | 17 | 2020 | 1394 | 1.490 |
Why?
|
| Intestinal Mucosa | 3 | 2018 | 186 | 1.460 |
Why?
|
| Nitro Compounds | 2 | 2020 | 10 | 1.440 |
Why?
|
| Benzopyrans | 2 | 2020 | 17 | 1.430 |
Why?
|
| Indoles | 2 | 2020 | 98 | 1.350 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2021 | 37 | 1.330 |
Why?
|
| Adenocarcinoma | 4 | 2014 | 284 | 1.320 |
Why?
|
| Resuscitation | 3 | 2016 | 59 | 1.270 |
Why?
|
| Dendritic Cells | 7 | 2021 | 141 | 1.240 |
Why?
|
| Mice | 28 | 2022 | 4408 | 1.190 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2019 | 12 | 1.140 |
Why?
|
| Polyethylene Glycols | 6 | 2013 | 93 | 1.100 |
Why?
|
| Tissue Distribution | 18 | 2022 | 132 | 1.060 |
Why?
|
| Ileum | 2 | 2016 | 23 | 1.000 |
Why?
|
| Inflammation Mediators | 4 | 2020 | 152 | 0.970 |
Why?
|
| Hippurates | 6 | 2015 | 25 | 0.920 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2019 | 80 | 0.880 |
Why?
|
| Neuroprotective Agents | 3 | 2016 | 51 | 0.870 |
Why?
|
| Lipopolysaccharides | 5 | 2021 | 152 | 0.860 |
Why?
|
| Cell Proliferation | 8 | 2020 | 771 | 0.820 |
Why?
|
| Chelating Agents | 2 | 2021 | 21 | 0.800 |
Why?
|
| Molecular Probes | 1 | 2021 | 13 | 0.770 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 26 | 0.760 |
Why?
|
| Cell Line, Tumor | 13 | 2020 | 1259 | 0.740 |
Why?
|
| Pancreas | 1 | 2021 | 58 | 0.740 |
Why?
|
| Male | 25 | 2020 | 12870 | 0.740 |
Why?
|
| Zinc | 1 | 2021 | 57 | 0.740 |
Why?
|
| Brain Ischemia | 1 | 2022 | 80 | 0.730 |
Why?
|
| Colchicine | 1 | 2020 | 15 | 0.730 |
Why?
|
| Tubulin | 1 | 2020 | 30 | 0.720 |
Why?
|
| Curcumin | 5 | 2014 | 67 | 0.720 |
Why?
|
| Tubulin Modulators | 1 | 2020 | 16 | 0.720 |
Why?
|
| Coronary Vessels | 1 | 2022 | 151 | 0.720 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 26 | 0.720 |
Why?
|
| Hypovolemia | 2 | 2013 | 3 | 0.680 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 3 | 0.680 |
Why?
|
| Ammonia | 1 | 2019 | 18 | 0.650 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 116 | 0.640 |
Why?
|
| Kidney | 4 | 2016 | 275 | 0.630 |
Why?
|
| Cyclotrons | 2 | 2019 | 11 | 0.620 |
Why?
|
| Nanoparticles | 2 | 2020 | 273 | 0.620 |
Why?
|
| Signal Transduction | 8 | 2024 | 1344 | 0.610 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 30 | 0.600 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 23 | 0.600 |
Why?
|
| Isoproterenol | 1 | 2017 | 23 | 0.600 |
Why?
|
| Liver | 5 | 2024 | 415 | 0.580 |
Why?
|
| Drug Carriers | 4 | 2014 | 109 | 0.570 |
Why?
|
| Stroke | 1 | 2020 | 233 | 0.560 |
Why?
|
| Lung | 4 | 2014 | 349 | 0.550 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 270 | 0.550 |
Why?
|
| Toll-Like Receptor 4 | 4 | 2021 | 70 | 0.540 |
Why?
|
| Plasma Substitutes | 1 | 2016 | 5 | 0.540 |
Why?
|
| Proteostasis Deficiencies | 1 | 2016 | 5 | 0.540 |
Why?
|
| Radioisotope Renography | 6 | 2016 | 29 | 0.530 |
Why?
|
| Nanotechnology | 1 | 2016 | 67 | 0.520 |
Why?
|
| Humans | 31 | 2024 | 26829 | 0.520 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 586 | 0.500 |
Why?
|
| Shock | 1 | 2015 | 17 | 0.490 |
Why?
|
| Oxygen | 2 | 2007 | 218 | 0.480 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2014 | 18 | 0.480 |
Why?
|
| Isotope Labeling | 5 | 2017 | 30 | 0.470 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 31 | 0.470 |
Why?
|
| NF-kappa B | 5 | 2019 | 187 | 0.460 |
Why?
|
| Drug Delivery Systems | 3 | 2014 | 216 | 0.450 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 3 | 2021 | 23 | 0.450 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2011 | 52 | 0.450 |
Why?
|
| Mice, Nude | 9 | 2014 | 313 | 0.440 |
Why?
|
| Phosphatidylethanolamines | 2 | 2004 | 23 | 0.440 |
Why?
|
| Polymers | 1 | 2014 | 114 | 0.440 |
Why?
|
| Palmitic Acid | 1 | 2013 | 10 | 0.430 |
Why?
|
| Transcription Factor RelA | 4 | 2013 | 21 | 0.430 |
Why?
|
| Apoptosis | 7 | 2020 | 739 | 0.420 |
Why?
|
| Molecular Structure | 5 | 2021 | 239 | 0.420 |
Why?
|
| CD13 Antigens | 4 | 2014 | 26 | 0.420 |
Why?
|
| Peptide Fragments | 3 | 2021 | 197 | 0.410 |
Why?
|
| Hydrazines | 1 | 2011 | 12 | 0.390 |
Why?
|
| Cytokines | 5 | 2021 | 438 | 0.380 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 72 | 0.380 |
Why?
|
| Cyclodextrins | 1 | 2011 | 4 | 0.370 |
Why?
|
| Necrosis | 2 | 2022 | 81 | 0.370 |
Why?
|
| Oxidative Stress | 2 | 2016 | 624 | 0.360 |
Why?
|
| Cell Line | 5 | 2021 | 673 | 0.360 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 28 | 0.360 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 101 | 0.350 |
Why?
|
| Models, Animal | 2 | 2010 | 129 | 0.350 |
Why?
|
| Dideoxynucleosides | 1 | 2010 | 12 | 0.340 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 42 | 0.340 |
Why?
|
| Pyruvic Acid | 3 | 2015 | 15 | 0.340 |
Why?
|
| Organotechnetium Compounds | 1 | 2009 | 2 | 0.330 |
Why?
|
| Cytarabine | 1 | 2009 | 4 | 0.330 |
Why?
|
| Bone Marrow | 1 | 2010 | 76 | 0.330 |
Why?
|
| Phospholipids | 1 | 2009 | 73 | 0.330 |
Why?
|
| Cell Survival | 5 | 2021 | 394 | 0.330 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 176 | 0.330 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 90 | 0.320 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 278 | 0.320 |
Why?
|
| Time Factors | 5 | 2016 | 1562 | 0.320 |
Why?
|
| Inflammation | 3 | 2022 | 601 | 0.310 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2013 | 32 | 0.310 |
Why?
|
| Oligopeptides | 3 | 2014 | 95 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2022 | 243 | 0.310 |
Why?
|
| Half-Life | 4 | 2014 | 32 | 0.290 |
Why?
|
| Drug Compounding | 3 | 2014 | 29 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 1476 | 0.280 |
Why?
|
| Radionuclide Imaging | 5 | 2014 | 56 | 0.280 |
Why?
|
| Transplantation, Heterologous | 2 | 2020 | 60 | 0.280 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 173 | 0.270 |
Why?
|
| Plant Extracts | 3 | 2011 | 60 | 0.270 |
Why?
|
| Structure-Activity Relationship | 2 | 2020 | 200 | 0.260 |
Why?
|
| Iodine Radioisotopes | 2 | 2011 | 35 | 0.260 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 211 | 0.250 |
Why?
|
| Nerve Growth Factor | 2 | 2015 | 14 | 0.250 |
Why?
|
| Oxidation-Reduction | 2 | 2020 | 354 | 0.250 |
Why?
|
| Adenosine Triphosphate | 2 | 2015 | 115 | 0.240 |
Why?
|
| NAD | 2 | 2015 | 81 | 0.240 |
Why?
|
| Drug Stability | 3 | 2014 | 23 | 0.240 |
Why?
|
| Blood Component Transfusion | 1 | 2004 | 13 | 0.240 |
Why?
|
| Capsid Proteins | 1 | 2004 | 12 | 0.230 |
Why?
|
| Metabolic Diseases | 1 | 2024 | 16 | 0.230 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 21 | 0.230 |
Why?
|
| Iodohippuric Acid | 2 | 2016 | 9 | 0.230 |
Why?
|
| Liver Diseases | 1 | 2024 | 51 | 0.220 |
Why?
|
| Complement Activation | 2 | 2014 | 25 | 0.220 |
Why?
|
| Rabbits | 5 | 2004 | 272 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2013 | 444 | 0.220 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 40 | 0.220 |
Why?
|
| Spectrometry, Gamma | 2 | 2019 | 7 | 0.220 |
Why?
|
| Drug Design | 2 | 2021 | 62 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2017 | 465 | 0.210 |
Why?
|
| Leukocytes | 1 | 2003 | 67 | 0.200 |
Why?
|
| Colitis | 1 | 2003 | 53 | 0.200 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2020 | 30 | 0.200 |
Why?
|
| Female | 10 | 2021 | 14463 | 0.200 |
Why?
|
| Streptavidin | 1 | 2022 | 11 | 0.200 |
Why?
|
| Infarction | 1 | 2022 | 8 | 0.200 |
Why?
|
| Fibronectins | 1 | 2022 | 28 | 0.200 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2022 | 16 | 0.200 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2002 | 39 | 0.200 |
Why?
|
| Neuroblastoma | 2 | 2013 | 56 | 0.190 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 73 | 0.190 |
Why?
|
| Energy Metabolism | 2 | 2015 | 178 | 0.190 |
Why?
|
| Azadirachta | 2 | 2011 | 3 | 0.190 |
Why?
|
| Colon | 1 | 2002 | 119 | 0.190 |
Why?
|
| Hydrogen Peroxide | 1 | 2022 | 139 | 0.190 |
Why?
|
| Kinetics | 2 | 2017 | 538 | 0.190 |
Why?
|
| Rosaceae | 2 | 2011 | 2 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 113 | 0.180 |
Why?
|
| Phosphorylation | 2 | 2013 | 560 | 0.180 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 46 | 0.180 |
Why?
|
| Perfusion | 1 | 2020 | 43 | 0.180 |
Why?
|
| Molecular Conformation | 1 | 2020 | 66 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2022 | 189 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2015 | 251 | 0.180 |
Why?
|
| Cell Death | 2 | 2010 | 110 | 0.170 |
Why?
|
| Interleukin-33 | 1 | 2019 | 5 | 0.170 |
Why?
|
| Sp1 Transcription Factor | 1 | 2019 | 17 | 0.170 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 214 | 0.170 |
Why?
|
| Pneumonia | 1 | 2020 | 89 | 0.170 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2019 | 5 | 0.160 |
Why?
|
| Transfection | 4 | 2013 | 313 | 0.160 |
Why?
|
| Neutrophils | 1 | 2020 | 177 | 0.160 |
Why?
|
| Methanol | 1 | 2019 | 14 | 0.160 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 43 | 0.160 |
Why?
|
| Up-Regulation | 1 | 2019 | 240 | 0.160 |
Why?
|
| Immunization | 2 | 2010 | 118 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2010 | 187 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2018 | 66 | 0.150 |
Why?
|
| Mutation | 2 | 2021 | 817 | 0.150 |
Why?
|
| Seizures | 1 | 2017 | 46 | 0.150 |
Why?
|
| Biological Transport | 1 | 2017 | 111 | 0.140 |
Why?
|
| Interferon-gamma | 2 | 2016 | 102 | 0.140 |
Why?
|
| Biomarkers | 1 | 2020 | 733 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 623 | 0.140 |
Why?
|
| Cycloheptanes | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hypoxia, Brain | 1 | 2016 | 5 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2015 | 108 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 453 | 0.140 |
Why?
|
| Narcotic Antagonists | 1 | 2016 | 31 | 0.130 |
Why?
|
| Particle Size | 2 | 2009 | 96 | 0.130 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 24 | 0.130 |
Why?
|
| Piperidines | 1 | 2016 | 42 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2016 | 32 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2017 | 198 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2016 | 43 | 0.130 |
Why?
|
| Hippocampus | 1 | 2017 | 185 | 0.130 |
Why?
|
| Protein Binding | 4 | 2021 | 632 | 0.130 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 36 | 0.130 |
Why?
|
| Blast Injuries | 1 | 2016 | 31 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 442 | 0.130 |
Why?
|
| Onium Compounds | 1 | 2015 | 8 | 0.130 |
Why?
|
| Eye Proteins | 1 | 2017 | 197 | 0.130 |
Why?
|
| Molecular Imaging | 2 | 2013 | 35 | 0.130 |
Why?
|
| Gamma Rays | 2 | 2013 | 26 | 0.130 |
Why?
|
| Phosphocreatine | 1 | 2015 | 22 | 0.130 |
Why?
|
| Peptides | 2 | 2015 | 280 | 0.130 |
Why?
|
| Glutathione | 2 | 2010 | 68 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 22 | 0.120 |
Why?
|
| Glucose-6-Phosphate | 1 | 2015 | 4 | 0.120 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2015 | 36 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 507 | 0.120 |
Why?
|
| Citrate (si)-Synthase | 1 | 2015 | 23 | 0.120 |
Why?
|
| Hexokinase | 1 | 2015 | 16 | 0.120 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 86 | 0.120 |
Why?
|
| Spleen | 3 | 2005 | 109 | 0.120 |
Why?
|
| Cell Line, Transformed | 2 | 2012 | 42 | 0.120 |
Why?
|
| Gelatinases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 18 | 0.120 |
Why?
|
| Whole Body Imaging | 1 | 2014 | 5 | 0.120 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2014 | 8 | 0.120 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 43 | 0.120 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 14 | 0.120 |
Why?
|
| Tight Junction Proteins | 1 | 2014 | 9 | 0.120 |
Why?
|
| Glycine | 1 | 2014 | 31 | 0.120 |
Why?
|
| Peroxidase | 1 | 2014 | 37 | 0.120 |
Why?
|
| Permeability | 1 | 2014 | 58 | 0.120 |
Why?
|
| Coordination Complexes | 1 | 2014 | 26 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2015 | 122 | 0.120 |
Why?
|
| Surface Properties | 1 | 2014 | 132 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2014 | 74 | 0.120 |
Why?
|
| Urothelium | 1 | 2014 | 35 | 0.120 |
Why?
|
| Pentetic Acid | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 261 | 0.110 |
Why?
|
| Heterografts | 1 | 2014 | 62 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 109 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2014 | 134 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 23 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 33 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2004 | 65 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 22 | 0.110 |
Why?
|
| Disease Progression | 1 | 2015 | 450 | 0.110 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2013 | 12 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 9 | 0.110 |
Why?
|
| Fibrosarcoma | 1 | 2013 | 12 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 38 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2013 | 282 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 68 | 0.110 |
Why?
|
| Fruit | 2 | 2011 | 38 | 0.110 |
Why?
|
| Methemoglobin | 1 | 2012 | 3 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 35 | 0.110 |
Why?
|
| Protein Stability | 1 | 2012 | 42 | 0.100 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 50 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 503 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 276 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2014 | 240 | 0.100 |
Why?
|
| Catalase | 1 | 2012 | 49 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 159 | 0.100 |
Why?
|
| Mitochondria | 1 | 2015 | 334 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2012 | 970 | 0.100 |
Why?
|
| Radioisotopes | 2 | 2014 | 10 | 0.100 |
Why?
|
| Technetium Tc 99m Mertiatide | 1 | 2011 | 4 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2264 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 80 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 439 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 747 | 0.090 |
Why?
|
| Cattle | 1 | 2012 | 383 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 17 | 0.090 |
Why?
|
| Fungal Vaccines | 1 | 2010 | 8 | 0.090 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 25 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 464 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 247 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2010 | 10 | 0.090 |
Why?
|
| Amino Acid Sequence | 3 | 2021 | 674 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 144 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 2010 | 30 | 0.090 |
Why?
|
| Liquid Ventilation | 1 | 2010 | 1 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 190 | 0.090 |
Why?
|
| Rats, Inbred WF | 1 | 2010 | 11 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2010 | 52 | 0.090 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2009 | 3 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2010 | 22 | 0.080 |
Why?
|
| Anions | 1 | 2009 | 15 | 0.080 |
Why?
|
| Autophagy | 1 | 2010 | 71 | 0.080 |
Why?
|
| Freezing | 1 | 2009 | 21 | 0.080 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 119 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2010 | 89 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 496 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2012 | 395 | 0.080 |
Why?
|
| Umbilical Cord | 1 | 2009 | 35 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2009 | 54 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2010 | 95 | 0.080 |
Why?
|
| Neoplasms, Experimental | 3 | 2015 | 57 | 0.080 |
Why?
|
| Antioxidants | 1 | 2010 | 220 | 0.080 |
Why?
|
| Organ Specificity | 2 | 2012 | 81 | 0.080 |
Why?
|
| Oxygen Radioisotopes | 1 | 2007 | 1 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 288 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 35 | 0.070 |
Why?
|
| Rhenium | 1 | 2007 | 5 | 0.070 |
Why?
|
| Film Dosimetry | 1 | 2007 | 8 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 46 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2007 | 65 | 0.070 |
Why?
|
| Macrophages | 1 | 2009 | 274 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 324 | 0.070 |
Why?
|
| Neoplasms | 1 | 2015 | 755 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 195 | 0.070 |
Why?
|
| Coccidioidomycosis | 1 | 2005 | 12 | 0.060 |
Why?
|
| Colloids | 1 | 2005 | 9 | 0.060 |
Why?
|
| Osmotic Pressure | 1 | 2005 | 9 | 0.060 |
Why?
|
| Drug Contamination | 1 | 2005 | 6 | 0.060 |
Why?
|
| Viscosity | 1 | 2005 | 37 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 151 | 0.060 |
Why?
|
| Fungal Proteins | 1 | 2005 | 72 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2005 | 118 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 486 | 0.060 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2004 | 1 | 0.060 |
Why?
|
| Serotyping | 1 | 2004 | 10 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2004 | 6 | 0.060 |
Why?
|
| Blood | 1 | 2004 | 33 | 0.060 |
Why?
|
| Indium Radioisotopes | 2 | 2005 | 7 | 0.050 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2003 | 4 | 0.050 |
Why?
|
| Dinitrochlorobenzene | 1 | 2003 | 1 | 0.050 |
Why?
|
| Whole-Body Counting | 1 | 2003 | 3 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 6 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 18 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2003 | 41 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2003 | 388 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 276 | 0.050 |
Why?
|
| Cholesterol | 1 | 2003 | 182 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 472 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 310 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 324 | 0.050 |
Why?
|
| Plant Leaves | 2 | 2011 | 55 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2021 | 172 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 1036 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2013 | 646 | 0.040 |
Why?
|
| DNA | 2 | 2011 | 365 | 0.040 |
Why?
|
| Coccidioides | 2 | 2010 | 14 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 266 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2010 | 76 | 0.040 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1998 | 1 | 0.040 |
Why?
|
| Deferoxamine | 1 | 1998 | 3 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 1998 | 77 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 2017 | 79 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 2016 | 26 | 0.030 |
Why?
|
| Proteome | 1 | 2016 | 75 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1998 | 246 | 0.030 |
Why?
|
| Halogenation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 64 | 0.030 |
Why?
|
| Neurons | 1 | 2017 | 275 | 0.030 |
Why?
|
| Motor Activity | 1 | 2016 | 146 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Acetates | 1 | 2014 | 44 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Alanine | 1 | 2014 | 40 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 75 | 0.030 |
Why?
|
| Clone Cells | 1 | 2013 | 20 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2013 | 25 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2014 | 78 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 61 | 0.030 |
Why?
|
| Telomerase | 1 | 2013 | 37 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 442 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2013 | 50 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 129 | 0.030 |
Why?
|
| Radiochemistry | 1 | 2012 | 10 | 0.030 |
Why?
|
| Recurrence | 1 | 2013 | 316 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 7 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 11 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 7 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2011 | 21 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 36 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 67 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 54 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 23 | 0.020 |
Why?
|
| Bacteria | 1 | 2014 | 263 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 43 | 0.020 |
Why?
|
| Arabinofuranosyluracil | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2010 | 6 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2010 | 12 | 0.020 |
Why?
|
| Cell Shape | 1 | 2010 | 15 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 58 | 0.020 |
Why?
|
| Transgenes | 1 | 2010 | 59 | 0.020 |
Why?
|
| Papio anubis | 1 | 2010 | 40 | 0.020 |
Why?
|
| Plasmids | 1 | 2010 | 122 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 66 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2010 | 58 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 91 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 3 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 13 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2010 | 7 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 100 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2010 | 4 | 0.020 |
Why?
|
| Phenols | 1 | 2010 | 22 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 43 | 0.020 |
Why?
|
| Epitopes | 1 | 2010 | 171 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 204 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 184 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 49 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 69 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 69 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 128 | 0.020 |
Why?
|
| Gene Expression | 1 | 2010 | 406 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 377 | 0.020 |
Why?
|
| Rats, Nude | 1 | 2007 | 5 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2007 | 7 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 102 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2005 | 25 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2005 | 35 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 1999 | 3 | 0.010 |
Why?
|